Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) Stock Price

AMLXStock

$26.34+73.63%52W

Market Cap$3.31B

P/E—

PEG Ratio—

Div yield—

Beta-0.08

AMLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)45.77%

Price vs S&P 500 (4W)-17.35%

VGM Score68.23

Book Value / Share (Quarterly)$2.15

P/TBV (Annual)2.61x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)574.28%

Cash Flow / Share (Quarterly)$-1.14

Price vs S&P 500 (YTD)106.12%

Gross Margin (TTM)82.75%

Net Profit Margin (TTM)-94.56%

EPS (TTM)$-1.43

10-Day Avg Trading Volume1.37M

EPS Excl Extra (TTM)$-1.43

Revenue Growth (5Y)127.75%

EPS (Annual)$-1.53

ROI (Annual)-47.41%

Gross Margin (Annual)63.22%

Net Profit Margin (5Y Avg)-7716.48%

Cash / Share (Quarterly)$2.25

ROA (Last FY)-43.51%

EBITD / Share (TTM)$-1.52

ROE (5Y Avg)-75.43%

Operating Margin (TTM)-99.16%

Cash Flow / Share (Annual)$-1.12

P/B Ratio13.82x

P/B Ratio (Quarterly)8.35x

Net Income / Employee (Annual)$-1,064,200

EV / Revenue (TTM)16.49x

Net Interest Coverage (TTM)-10.93x

ROA (TTM)-48.53%

EV / EBITDA (TTM)81.64x

EPS Incl Extra (Annual)$-1.53

Current Ratio (Annual)14.27x

Quick Ratio (Quarterly)11.86x

3-Month Avg Trading Volume2.15M

52-Week Price Return73.63%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.20

P/S Ratio (Annual)37.84x

Asset Turnover (Annual)0.45x

52-Week High$41.14

Operating Margin (5Y Avg)-7253.97%

EPS Excl Extra (Annual)$-1.53

CapEx CAGR (5Y)-1.78%

26-Week Price Return55.67%

Quick Ratio (Annual)13.98x

13-Week Price Return48.39%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.12x

Enterprise Value$3.26B

Revenue / Share Growth (5Y)119.26%

Asset Turnover (TTM)0.50x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-345.81%

Cash / Share (Annual)$2.88

3-Month Return Std Dev138.44%

Net Income / Employee (TTM)$-1,118,300

ROE (Last FY)-47.41%

EPS Basic Excl Extra (Annual)$-1.53

Receivables Turnover (TTM)0.00x

EV / Free Cash Flow (TTM)410.90x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.43

Receivables Turnover (Annual)0.00x

ROI (TTM)-52.92%

P/S Ratio (TTM)16.83x

Pretax Margin (5Y Avg)-7715.61%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.12

Price vs S&P 500 (52W)58.10%

Year-to-Date Return118.05%

5-Day Price Return-4.15%

EPS Normalized (Annual)$-1.53

ROA (5Y Avg)-64.75%

Net Profit Margin (Annual)-345.36%

Month-to-Date Return-9.48%

Cash Flow / Share (TTM)$0.04

EBITD / Share (Annual)$-1.62

Operating Margin (Annual)-360.22%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-75.43%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.43

P/TBV (Quarterly)2.13x

P/B Ratio (Annual)4.35x

Inventory Turnover (TTM)1.68x

Pretax Margin (TTM)-93.56%

Book Value / Share (Annual)$2.78

Price vs S&P 500 (13W)45.71%

Beta-0.08x

P/FCF (Annual)309.61x

Revenue / Share (TTM)$0.00

ROE (TTM)-52.92%

52-Week Low$10.83

vGradeD

gGradeA

mGradeA

vgmGradeB

AMLX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.36	-$0.39	-9.04%(-$0.03)
Q1 2026	May 7, 2026	-$0.34	-$0.37	-8.71%(-$0.03)
Q4 2025	Mar 3, 2026	-$0.34	-$0.30	+12.23%(+$0.04)
Q3 2025	Nov 6, 2025	-$0.43	-$0.37	+13.93%(+$0.06)
Q2 2025	Aug 7, 2025	-$0.45	-$0.46	-1.23%(-$0.01)

AMLX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.33

4.35

4.39

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AMLXAmylyx Pharmaceuticals, Inc. Common Stock	D	A	A	16.8x	—	82.8%	—	$26.34
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for amyotrophic lateral sclerosis, neurodegenerative diseases, and endocrine disorders. The company is focused on addressing unmet medical needs in these therapeutic areas.

AMLX Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.37

Revenue estimate$41,600

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AMLX Insider Transactions

SellOct 5, 2026
MILNE GEORGE MCLEAN JR
Director
Shares: 30,000Value: $830,904
SellSep 10, 2026
COHEN JOSHUA BARRY
Chief Executive Officer
Shares: 30,464Value: $980,504
SellSep 10, 2026
KLEE JUSTIN B
Chief Executive Officer
Shares: 30,464Value: $980,263
SellSep 10, 2026
FRATES JAMES MATTHEW
Chief Financial Officer
Shares: 10,810Value: $349,821
SellSep 10, 2026
BEDROSIAN CAMILLE L
Officer
Shares: 10,028Value: $324,868

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

ADPTAdaptive Biotechnologies Corporation Common StockBiological Products
IPARInterparfums, Inc. Common StockCosmetics & Toiletries
AVNTAvient CorporationPlastics & Resins
RLAYRelay Therapeutics, Inc. Common StockBiological Products
TARSTarsus Pharmaceuticals, Inc. Common StockBiological Products
SMGThe Scotts Miracle-Gro CompanyAgricultural Chemicals
COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.4

Strong Buy

Consensus rating

52-Week Range

Low$10.83

High$41.14